Flaherty Devin C, Hoffner Brianna W, Lau Briana J, Hamid Omid, Faries Mark B
Division of Surgical Oncology, John Wayne Cancer Institute at Providence Saint John's Health Center, Santa Monica, California.
The Angeles Clinic and Research Institute, Los Angeles, California.
J Surg Oncol. 2015 Dec;112(8):844-5. doi: 10.1002/jso.24078. Epub 2015 Oct 26.
A middle-aged female with metastatic melanoma was found to have hemoperitoneum after starting systemic therapy with the BRAF and MEK inhibitors dabrafenib and trametinib. Etiology proved to be bleeding from a known hepatic metastasis. The patient was managed conservatively and eventually resumed systemic therapy with ongoing response. This case serves to illustrate the possible deleterious effects of rapid tumor response after initiation of targeted systemic therapy in patients with metastatic melanoma.
一名患有转移性黑色素瘤的中年女性在开始使用BRAF和MEK抑制剂达拉非尼和曲美替尼进行全身治疗后出现腹腔积血。病因被证实是已知肝转移灶出血。患者接受了保守治疗，最终恢复全身治疗并持续有反应。该病例旨在说明转移性黑色素瘤患者在开始靶向全身治疗后肿瘤快速反应可能产生的有害影响。
